---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-126061"
form_type: "8-K"
ticker: "PRPO"
cik: "0001043961"
company_name: "Precipio, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:30:32.252735+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Precipio achieves two of three 2023 goals; revenue up ~50% YoY, cash burn cut 60%

## Summary
- Pathology division hit $14M annualized revenue in Q3, meeting target #1; product target lowered to $6M.
- Quarterly cash burn reduced from $2.5M (Q3-2022) to $1M (Q3-2023), exceeding target #3.
- Q3 2023 total revenue $4.5M (50% YoY gain); annualized run-rate ~$18.5M.
- Expects Q4 2023 revenue $3.2-$3.5M, FY 2023 total ~$14.5M vs $9.8M in 2022.
- If ~50% growth continues, positive cash flow possible in H2 2024 at ~$30M annual run-rate.

## SEC filing metadata
- accession: 0001104659-23-126061
- form_type: 8-K
- ticker: PRPO
- cik: 0001043961
- company_name: Precipio, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1043961/000110465923126061/0001104659-23-126061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1043961/000110465923126061/tm2332910d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-126061
- JSON: https://secwatch.observer/filing/0001104659-23-126061.json
- Plain text: https://secwatch.observer/filing/0001104659-23-126061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.